Free Trial

Capstone Therapeutics (CAPS) Competitors

Capstone Therapeutics logo
$1.60 -0.01 (-0.31%)
As of 07/25/2025 03:57 PM Eastern

CAPS vs. PTPI, TRVN, PBLA, SRNE, ZVSA, BPTSY, VRPX, HEPA, VIRX, and NCNA

Should you be buying Capstone Therapeutics stock or one of its competitors? The main competitors of Capstone Therapeutics include Petros Pharmaceuticals (PTPI), Trevena (TRVN), Panbela Therapeutics (PBLA), Sorrento Therapeutics (SRNE), ZyVersa Therapeutics (ZVSA), Biophytis (BPTSY), Virpax Pharmaceuticals (VRPX), Hepion Pharmaceuticals (HEPA), Viracta Therapeutics (VIRX), and NuCana (NCNA). These companies are all part of the "pharmaceutical products" industry.

Capstone Therapeutics vs. Its Competitors

Petros Pharmaceuticals (NASDAQ:PTPI) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Petros Pharmaceuticals has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500. Comparatively, Capstone Therapeutics has a beta of -0.82, suggesting that its stock price is 182% less volatile than the S&P 500.

Capstone Therapeutics' return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Petros PharmaceuticalsN/A -78.22% -23.50%
Capstone Therapeutics N/A N/A N/A

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 2.6% of Capstone Therapeutics shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by insiders. Comparatively, 42.8% of Capstone Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Capstone Therapeutics has higher revenue and earnings than Petros Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Petros Pharmaceuticals$5.11M0.19-$8.16M-$60.870.00
Capstone Therapeutics$44.88M0.01-$2.56MN/AN/A

In the previous week, Capstone Therapeutics had 1 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 1 mentions for Capstone Therapeutics and 0 mentions for Petros Pharmaceuticals. Capstone Therapeutics' average media sentiment score of 1.87 beat Petros Pharmaceuticals' score of 0.00 indicating that Capstone Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Petros Pharmaceuticals Neutral
Capstone Therapeutics Very Positive

Summary

Capstone Therapeutics beats Petros Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

Get Capstone Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CAPS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CAPS vs. The Competition

MetricCapstone TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$250K$3.06B$5.69B$9.50B
Dividend YieldN/A2.37%4.58%4.01%
P/E RatioN/A21.1828.1020.05
Price / Sales0.01288.50432.4490.07
Price / CashN/A42.7636.2258.56
Price / Book-0.088.378.665.87
Net Income-$2.56M-$55.19M$3.25B$258.55M
7 Day Performance-1.54%5.88%4.23%3.74%
1 Month Performance-6.18%17.33%10.52%11.75%
1 Year PerformanceN/A4.42%34.41%18.03%

Capstone Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CAPS
Capstone Therapeutics
N/A$1.60
-0.3%
N/AN/A$250K$44.88M0.0038
PTPI
Petros Pharmaceuticals
N/A$0.03
flat
N/A-99.7%$897K$5.11M-0.0120Gap Down
TRVN
Trevena
1.1673 of 5 stars
$0.91
flat
$5.00
+449.5%
-84.0%$873K$443K-0.0240
PBLA
Panbela Therapeutics
0.2989 of 5 stars
$0.16
-13.9%
N/A-53.1%$777KN/A0.006
SRNE
Sorrento Therapeutics
0.4922 of 5 stars
$0.00
-12.5%
N/A-87.2%$772K$60.32M0.00800Gap Down
ZVSA
ZyVersa Therapeutics
0.1938 of 5 stars
$0.14
-22.5%
N/A-93.0%$696KN/A0.002Gap Up
BPTSY
Biophytis
N/A$1.81
+35.7%
N/AN/A$634KN/A0.0030Gap Up
VRPX
Virpax Pharmaceuticals
N/A$0.40
-9.1%
N/A-99.9%$497KN/A0.007Gap Down
HEPA
Hepion Pharmaceuticals
0.1279 of 5 stars
$0.04
-2.8%
N/A-99.9%$462KN/A-0.0120Gap Up
VIRX
Viracta Therapeutics
2.567 of 5 stars
$0.01
flat
$1.75
+17,793.7%
N/A$389KN/A-0.0120
NCNA
NuCana
3.318 of 5 stars
$0.05
+1.9%
$25.00
+52,310.9%
-98.3%$280KN/A-0.0130Gap Up

Related Companies and Tools


This page (NASDAQ:CAPS) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners